The estimated Net Worth of Jung Choi is at least $25.1 Millón dollars as of 27 September 2022. Ms. Choi owns over 99,489 units of Global Blood Therapeutics stock worth over $20,583,094 and over the last 9 years she sold GBT stock worth over $1,229,400. In addition, she makes $3,279,330 as Chief Business and Strategy Officer at Global Blood Therapeutics.
Jung has made over 22 trades of the Global Blood Therapeutics stock since 2015, according to the Form 4 filled with the SEC. Most recently she exercised 99,489 units of GBT stock worth $700,403 on 27 September 2022.
The largest trade she's ever made was exercising 99,489 units of Global Blood Therapeutics stock on 27 September 2022 worth over $700,403. On average, Jung trades about 5,619 units every 63 days since 2015. As of 27 September 2022 she still owns at least 300,527 units of Global Blood Therapeutics stock.
You can see the complete history of Ms. Choi stock trades at the bottom of the page.
Jung E. Choi serves as Chief Business and Strategy Officer of the Company. From April 2014 to March 2015, Ms. Choi served as senior vice president, corporate development for InterMune, Inc., a biotechnology company (acquired by Roche Holding AG in 2014), and served as an adviser on strategy and business development to InterMune from March 2013 to April 2014. Prior to joining InterMune, from February 2011 to March 2013, Ms. Choi led corporate and business development for Chimerix, Inc., a biopharmaceutical company, as a consultant and senior vice president, corporate development. Prior to that, from August 2001 to August 2010, Ms. Choi held various management positions at Gilead Sciences, Inc., a biopharmaceutical company, including leadership of business development, licensing, and mergers and acquisition activities. During her tenure at Gilead Sciences, Ms. Choi built and oversaw the corporate development group, and led the U.S. commercial launch of Hepsera® for the treatment of the hepatitis B virus. Ms. Choi holds a B.A. in human biology and an M.B.A. from Stanford University.
As the Chief Business and Strategy Officer of Global Blood Therapeutics, the total compensation of Jung Choi at Global Blood Therapeutics is $3,279,330. There are 3 executives at Global Blood Therapeutics getting paid more, with Ted Love having the highest compensation of $10,097,200.
Jung Choi is 50, she's been the Chief Business and Strategy Officer of Global Blood Therapeutics since 2015. There are 19 older and 1 younger executives at Global Blood Therapeutics. The oldest executive at Global Blood Therapeutics Inc. is Willie Brown, 86, who is the Independent Director.
Jung's mailing address filed with the SEC is C/O GLOBAL BLOOD THERAPEUTICS, INC., 181 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA, 94080.
Over the last 9 years, insiders at Global Blood Therapeutics have traded over $164,753,446 worth of Global Blood Therapeutics stock and bought 255,000 units worth $8,595,265 . The most active insiders traders include Advisors Llcperceptive Life..., Rock Ventures Ii, L.P.Third... y Kevin P Starr. On average, Global Blood Therapeutics executives and independent directors trade stock every 14 days with the average trade being worth of $3,133,144. The most recent stock trade was executed by Nazila Habibizad on 1 October 2022, trading 1,557 units of GBT stock currently worth $106,639.
Global Blood Therapeutics (GBT) is a biopharmaceutical company dedicated to the discovery, development, and delivery of life-changing treatments that provide hope to underserved patient communities. Founded in 2011, GBT is delivering on its goal to transform the treatment and care of sickle cell disease (SCD), a lifelong, devastating inherited blood disorder. The company has introduced Oxbryta® (voxelotor) tablets, the first FDA-approved treatment that directly inhibits sickle hemoglobin polymerization, the root cause of red blood cell sickling in SCD. GBT is also advancing its pipeline program in SCD with inclacumab, a P-selectin inhibitor in development to address pain crises associated with the disease, and GBT021601 (GBT601), the company's next generation hemoglobin S polymerization inhibitor. In addition, GBT's drug discovery teams are working on new targets to develop the next wave of treatments for SCD.
Global Blood Therapeutics executives and other stock owners filed with the SEC include: